Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. De plus, nous expédions Sclerostin Kits (63) et Sclerostin Protéines (18) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 128 products:
Human Polyclonal Sclerostin Primary Antibody pour EIA, IHC (p) - ABIN358751
Semenov, He: LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. dans The Journal of biological chemistry 2006
Show all 3 Pubmed References
Human Polyclonal Sclerostin Primary Antibody pour IHC (p), WB - ABIN390193
Lin, Lin, Chang, Wang, Lai: Single-pulsed electromagnetic field therapy increases osteogenic differentiation through Wnt signaling pathway and sclerostin downregulation. dans Bioelectromagnetics 2015
Show all 2 Pubmed References
High serum levels of sclerostin and Dkk-1 (Montrer DKK1 Anticorps) are associated with acute ischaemic stroke
The increased expression of sclerostin in the liver and the association with histologic cholangitis may explain the high serum levels of this protein in patients with primary biliary cirrhosis.
SOST silencing promotes the proliferation, invasion and migration, and decreases the apoptosis of human retinoblastoma cells by activating the Wnt (Montrer WNT2 Anticorps)/beta-catenin (Montrer CTNNB1 Anticorps) signaling pathway.
Sclerostin concentrations in serum significantly decreased and IGF-I (Montrer IGF1 Anticorps) significantly increased after 12months of resistance training or JUMP.
observed an association between sclerostin levels with fasting insulin (Montrer INS Anticorps) levels and homoeostatic model assessment-insulin (Montrer INS Anticorps) resistance, but there was no clear association with type 2 diabetes risk.
Sclerostin levels in KTR are normal and influenced more by bone turnover than by eGFR (Montrer EGFR Anticorps). Its involvement with other hormones of mineral homeostasis (FGF23 (Montrer FGF23 Anticorps)/Klotho (Montrer KL Anticorps) and Vitamin D) is part of the sophisticated cross-talk between bone and the kidney
In chronic kidney disease, serum levels of the Wnt (Montrer WNT2 Anticorps) inhibitors DKK1 (Montrer DKK1 Anticorps) and sclerostin are unrelated, indicating different sites of origin and/ or different regulatory mechanisms. Sclerostin, as opposed to DKK1 (Montrer DKK1 Anticorps), may qualify as a biomarker of chronic kidney disease-mineral and bone and mineral disorder (CKD-MBD (Montrer DPEP1 Anticorps)), particularly in dialysis patients.
Vitamin D receptor (Montrer VDR Anticorps) agonism by paricalcitol causes a moderate increase in serum sclerostin in CKD patients, and this effect is modified by circulating pentosidine levels.
SOST is frequently expressed in skeletal bone- and cartilage-forming tumors. The strong spatial correlation with bone formation and the in vitro expression patterns are in line with the known functions of SOST in nonneoplastic bone, as a feedback inhibitor on osteogenic differentiation.
Intermittent compressive stress regulates Notch (Montrer NOTCH1 Anticorps) receptor and target gene expression via the TGF-beta (Montrer TGFB1 Anticorps) signaling pathway. Notch (Montrer NOTCH1 Anticorps) signaling participates in TGF-beta (Montrer TGFB1 Anticorps)-induced sclerostin expression in periodontal ligament cells.
loss of BMP signaling specifically in osteocytes dramatically increases bone mass presumably through simultaneous inhibition of RANKL (Montrer TNFSF11 Anticorps) and SOST, leading to osteoclast inhibition and Wnt (Montrer WNT2 Anticorps) activation together.
humanized Multiple Myeloma xenograft mouse model bearing human MM cells (NOD-SCID.CB17 male mice injected intravenously with 2.5 million of MM1 (Montrer PFDN5 Anticorps).S-Luc-GFP cells) demonstrated significantly higher concentrations of mouse-derived sclerostin, suggesting a microenvironmental source of sclerostin.
Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin
Osteocyte-derived molecule sclerostin drives bone marrow adipogenesis.
complete absence of sclerostin has only minor effects on chronic kidney disease-induced bone loss in mice.
In mice, sclerostin deficiency hastened reparative dentinogenesis after pulp injury, suggesting that the inhibition of sclerostin may constitute a promising therapeutic strategy for improving the healing of damaged pulps.
These data suggest that sclerostin plays an important role in the bone remodeling of tooth movement.
Sclerostin inhibits angiotensin II-induced aortic aneurysm and atherosclerosis via wnt (Montrer WNT2 Anticorps) signaling pathway inhibition.
Analysis of SOST expression using large minigenes reveals the MEF2C (Montrer MEF2C Anticorps) binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D3 or TGFbeta1 (Montrer TGFB1 Anticorps) responsiveness.
removal of sclerostin appears to modestly protect the alveolar bone from resorption in this experimental setting
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.